Ovarian cancer has the highest mortality rate among all gynecologic cancers, with most
patients presenting with advanced stage tumors. About a third of patients do not respond to
primary platinum-based chemotherapy treatment, and over time up to 80 % of others develop
chemoresistance, rendering recurrent disease incurable. Despite all the studies published in
the literature, it has not been proven that the number of cells with expressed ATP7A in
certain tumors increases independently of the therapy. In addition, no study has been
conducted on a sample of patients with confirmed serous histology of ovarian cancer only. The
aim of the study is to demonstrate increased expression of the ATP7A transporter in cells
resistant to carboplatin.